Dr. Richard Brown -- Pharma Payment Report

Payment Summary

• Total Payments Received: $19,727.81
• Number of Transactions: 1
• Transparency Score: 50/100

Payment Breakdown

• speaking: $0.00
• travel: $0.00
• ownership: $0.00
• consulting: $19,727.81
• research: $0.00
• meals: $0.00

AI Analysis

Dr. Richard Brown, a cardiologist in City, CO, has a pharmaceutical payment profile characterized by a single, substantial payment. With a total of $19,727.81 from Pfizer Inc., this represents the entirety of his reported payments. This payment is categorized as consulting and is dated for August 8, 2025. Comparing this to the broader field of Cardiology, Dr. Brown's total payment volume is significantly lower than the average. Cardiologists, on average, receive a more consistent and higher volume of payments from various pharmaceutical companies, often reflecting ongoing research collaborations, speaker engagements, or advisory roles. The singular nature of Dr. Brown's payment, originating solely from Pfizer Inc., is noteworthy. While it's impossible to definitively ascertain the exact nature or implications of this specific consulting arrangement without further details, it suggests a focused relationship with this particular company. The payment breakdown for Dr. Brown is entirely concentrated in consulting, with no reported income from speaking engagements, meals, travel, research, or ownership interests. This singular focus on consulting, especially a single large payment, deviates from the more diversified payment streams often seen among specialists who engage frequently with pharmaceutical companies. Whether this pattern warrants closer attention is debatable. On one hand, the total volume is low, and the payment is for a future date, suggesting a planned professional activity. On the other hand, the substantial amount of a single payment from one company could indicate a significant advisory role or a specific project. Without more data points or context on the nature of the consulting, it's difficult to label it as routine professional activity or a cause for immediate concern. It is a pattern that warrants understanding the specifics of the consulting agreement. For patient care, it's crucial to understand that pharmaceutical payments can influence physician behavior, including prescribing habits and the adoption of new treatments. While doctors are expected to maintain objectivity, even small payments can create unconscious biases. Patients should be aware that their doctor may have financial ties to companies whose medications they prescribe. This doesn't automatically mean a doctor is providing suboptimal care, but it does highlight the importance of transparency and open communication. Patients should feel empowered to discuss treatment options and any potential conflicts of interest with their physician. Patients should know that while Dr. Brown's reported payments are limited, the nature of the single, large consulting fee from Pfizer Inc. is a point of interest. It is advisable for patients to engage in open dialogue with their cardiologist about all treatment options, including generics and alternatives, and to understand the rationale behind prescribed medications. Transparency in these financial relationships is key to fostering trust and ensuring that patient well-being remains the primary focus.

Patient Guidance

When considering your doctor's financial relationships with pharmaceutical companies, it's important to approach the information with a balanced perspective. These payments can range from routine professional activities, like consulting or speaking on new research, to more significant advisory roles. At your next appointment, consider asking your doctor: 'Are there any financial relationships you have with pharmaceutical companies that might be relevant to the treatments we are discussing?' or 'Could you explain the different treatment options available, including any potential benefits and drawbacks of each?' Red flags to watch for include a doctor who seems overly enthusiastic about a particular drug without a clear clinical justification, or who dismisses alternative treatments without thorough consideration. While occasional meals or small payments for educational events are common and generally not concerning, a pattern of large, frequent payments, especially for consulting or speaking, from companies whose drugs are frequently prescribed by the doctor, might warrant closer scrutiny. It's crucial to remember that a doctor's relationship with pharmaceutical companies doesn't automatically equate to compromised care. Many physicians maintain these relationships to stay informed about advancements. However, awareness of these ties allows you to have more informed conversations and ensure that your treatment plan is based on your individual needs and the best available evidence, not solely on industry influence. Evaluate your doctor's prescribing patterns by looking at whether they favor newer, more expensive drugs over equally effective, less costly alternatives, and discuss this with them.

Peer Comparison

The average cardiologist receives a more substantial and diversified stream of payments from pharmaceutical companies, often ranging from several thousand to tens of thousands of dollars annually across multiple interactions. Dr. Brown's total payment of $19,727.81, while significant in its singular nature, is likely below the average annual total for active cardiologists engaged in industry relationships. His profile is atypical due to the single payment from one company.

Recent Payments

Frequently Asked Questions

Is Dr. Richard Brown taking too much pharma money?

Dr. Brown's reported pharmaceutical payments consist of a single consulting fee of $19,727.81 from Pfizer Inc., scheduled for 2025. While this is a substantial amount for a single transaction, it is a solitary payment. Compared to the average cardiologist who may receive more frequent and diversified payments, Dr. Brown's total volume is limited. The key factor is the nature of the consulting agreement. If it represents legitimate advisory work that enhances his knowledge and patient care, it may be acceptable. However, any single large payment warrants understanding the context to ensure it doesn't create undue influence.

What pharma companies pay Dr. Richard Brown?

Dr. Richard Brown receives payments exclusively from Pfizer Inc. The total amount reported is $19,727.81. This payment is designated for consulting services and is scheduled for August 8, 2025.

Should I switch doctors because of pharma payments?

Switching doctors solely based on pharmaceutical payments is a significant decision that should be made with careful consideration. If your doctor has disclosed financial relationships and you feel comfortable discussing them and their potential impact on your care, it may not be necessary to switch. However, if you experience red flags such as a lack of transparency, dismissal of your concerns, or a consistent pattern of prescribing expensive medications without clear justification, it might be time to seek a second opinion or a new physician. Trust and open communication are paramount in the doctor-patient relationship.

What kinds of payments does this doctor receive?

Dr. Richard Brown's reported payments are exclusively for consulting. He has received no payments for speaking, meals, travel, research, or ownership interests from pharmaceutical companies. This indicates a singular type of financial relationship with the industry.

How do these payments compare to other Cardiology?

The average cardiologist typically receives a more consistent and varied range of payments from pharmaceutical companies, often totaling several thousand dollars annually across multiple interactions. Dr. Brown's profile, with a single payment of $19,727.81, is less common. While the total amount is significant for one transaction, it is likely lower than the aggregate annual payments received by many of his peers who engage more frequently with industry.

Do pharma payments affect prescribing quality?

Research suggests that even small financial incentives from pharmaceutical companies can influence physician prescribing patterns, potentially leading to increased prescription of the paying company's drugs. While many physicians strive for objectivity, unconscious biases can be at play. Evidence indicates that doctors who receive payments may be more likely to prescribe newer, more expensive medications. However, this does not mean all payments lead to compromised care; many physicians use these relationships to stay informed. Transparency and critical evaluation of prescribing habits are key.

How can I verify this payment data?

You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This publicly accessible website allows you to search for physicians and teaching hospitals to view their financial relationships with the pharmaceutical and medical device industries. You can access it by searching for 'CMS Open Payments' online and using the search tools provided on their official website.